OCSE:GMAB (Denmark)  
Genmab A/S logo

Genmab A/S

kr 3233.00 (+1.99%) Nov 28
P/E:
37.72
P/B:
7.98
Market Cap:
kr 213.01B ($ 29.58B)
Enterprise V:
kr 189.85B ($ 26.36B)
Volume:
113.60K
Avg Vol (2M):
110.44K
Also Trade In:
Volume:
113.60K
Market Cap kr:
213.01B
Market Cap $:
29.58B
PE Ratio:
37.72
Avg Vol (2-Month):
110.44K
Enterprise Value kr:
189.85B
Enterprise Value $:
26.36B
PB Ratio:
7.98
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Name Current Vs Industry Vs History
Cash-To-Debt 37.82
Equity-to-Asset 0.87
Debt-to-Equity 0.02
Debt-to-EBITDA 0.08
Interest Coverage 21.13
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 34.58
Distress
Grey
Safe
Beneish M-Score -2.5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 74.91
9-Day RSI 72.2
14-Day RSI 70.06
6-1 Month Momentum % 37.66
12-1 Month Momentum % 12.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.62
Quick Ratio 9.62
Cash Ratio 7.96
Days Sales Outstanding 111.15

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.3

Financials (Next Earnings Date:2023-02-16 Est.)

OCSE:GMAB's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 11,987
EPS (TTM) (kr) 85.7
Beta 1.38
Volatility % 38.49
14-Day RSI 70.06
14-Day ATR (kr) 82.009881
20-Day SMA (kr) 3062.9
12-1 Month Momentum % 12.46
52-Week Range (kr) 1863 - 3244
Shares Outstanding (Mil) 65.89

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Genmab A/S Filings

Document Form Filing Date
No Filing Data

Genmab A/S Analysis

Share your research